A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

BACKGROUND: 13‐Deoxy, 5‐iminodoxorubicin (GPX‐150) is a doxorubicin (DOX) analog synthesized to reduce the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irreversible, cumulative dose‐dependent cardiotoxicity of DOX. In a...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Tine, Brian A., Agulnik, Mark, Olson, Richard D., Walsh, Gerald M., Klausner, Arthur, Frank, Nicole E., Talley, Todd T., Milhem, Mohammed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558450/
https://www.ncbi.nlm.nih.gov/pubmed/31016866
http://dx.doi.org/10.1002/cam4.2136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558450/
https://www.ncbi.nlm.nih.gov/pubmed/31016866
http://dx.doi.org/10.1002/cam4.2136

Ejemplares similares